Takeda Pharmaceutical Company Limited
4502.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.32 | -0.06 | 0.03 | -0.94 |
| FCF Yield | 4.78% | 2.25% | 2.05% | 4.64% |
| EV / EBITDA | 34.03 | 25.18 | 88.49 | 44.44 |
| Quality | ||||
| ROIC | -0.23% | 1.29% | 0.24% | 1.04% |
| Gross Margin | 65.85% | 53.35% | 51.49% | 51.77% |
| Cash Conversion Ratio | -32.25 | 1.64 | -1.86 | 14.82 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.06% | 2.89% | 4.39% | 5.10% |
| Free Cash Flow Growth | 108.70% | 9.14% | -53.53% | 46.70% |
| Safety | ||||
| Net Debt / EBITDA | 12.53 | 9.45 | 36.34 | 17.60 |
| Interest Coverage | 0.83 | 1.78 | 0.61 | 4.80 |
| Efficiency | ||||
| Inventory Turnover | 0.29 | 0.42 | 0.42 | 0.44 |
| Cash Conversion Cycle | 260.57 | 198.09 | 192.60 | 186.06 |